Accredited Investors Inc. cut its stake in Express Scripts Holding (NASDAQ:ESRX) by 15.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,934 shares of the company’s stock after selling 695 shares during the quarter. Accredited Investors Inc.’s holdings in Express Scripts were worth $294,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Nordea Investment Management AB raised its stake in shares of Express Scripts by 1.4% in the second quarter. Nordea Investment Management AB now owns 7,116,445 shares of the company’s stock worth $454,314,000 after purchasing an additional 97,953 shares during the last quarter. Van ECK Associates Corp raised its stake in shares of Express Scripts by 5.1% in the third quarter. Van ECK Associates Corp now owns 506,511 shares of the company’s stock worth $32,072,000 after purchasing an additional 24,728 shares during the last quarter. Lazard Asset Management LLC raised its stake in shares of Express Scripts by 81.8% in the second quarter. Lazard Asset Management LLC now owns 112,666 shares of the company’s stock worth $7,192,000 after purchasing an additional 50,707 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Express Scripts by 12.5% in the third quarter. Victory Capital Management Inc. now owns 35,421 shares of the company’s stock worth $2,243,000 after purchasing an additional 3,940 shares during the last quarter. Finally, Marco Investment Management LLC purchased a new stake in shares of Express Scripts during the second quarter valued at approximately $1,797,000. 88.21% of the stock is owned by hedge funds and other institutional investors.
In related news, CEO Timothy C. Wentworth purchased 8,000 shares of the business’s stock in a transaction dated Tuesday, October 31st. The stock was purchased at an average cost of $61.13 per share, with a total value of $489,040.00. Following the completion of the acquisition, the chief executive officer now directly owns 98,628 shares of the company’s stock, valued at $6,029,129.64. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Christine Houston sold 10,104 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $70.08, for a total value of $708,088.32. Following the completion of the transaction, the vice president now directly owns 87,400 shares of the company’s stock, valued at $6,124,992. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,644 shares of company stock valued at $1,289,609. 0.68% of the stock is owned by corporate insiders.
Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.90 earnings per share for the quarter, meeting the consensus estimate of $1.90. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The business had revenue of $24.68 billion during the quarter, compared to analyst estimates of $25.68 billion. During the same period in the prior year, the company earned $1.74 earnings per share. Express Scripts’s revenue was down 2.9% compared to the same quarter last year. equities research analysts anticipate that Express Scripts Holding will post 7.04 earnings per share for the current fiscal year.
Express Scripts declared that its board has approved a share buyback program on Monday, December 18th that authorizes the company to repurchase 45,000,000 shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
A number of analysts recently commented on ESRX shares. Royal Bank of Canada started coverage on Express Scripts in a research report on Tuesday, September 19th. They set a “sector perform” rating and a $68.00 price target for the company. ValuEngine raised Express Scripts from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. UBS Group downgraded Express Scripts from a “market perform” rating to an “underperform” rating in a research report on Monday, October 9th. Raymond James Financial reaffirmed an “underperform” rating on shares of Express Scripts in a research report on Monday, October 9th. Finally, Zacks Investment Research raised Express Scripts from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research report on Monday, October 16th. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $77.09.
ILLEGAL ACTIVITY WARNING: “Accredited Investors Inc. Has $294,000 Stake in Express Scripts Holding (ESRX)” was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3142772/accredited-investors-inc-has-294000-stake-in-express-scripts-holding-esrx.html.
About Express Scripts
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Want to see what other hedge funds are holding ESRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Express Scripts Holding (NASDAQ:ESRX).
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.